Diclofenac Sodium Extended-release Generic Name & Formulations
Diclofenac sodium 100mg; ext-rel tabs.
NSAID (benzeneacetic acid deriv.).
Diclofenac Sodium Extended-release Indications
Chronic therapy of osteoarthritis or rheumatoid arthritis.
Diclofenac Sodium Extended-release Dosage and Administration
Use lowest effective dose for shortest duration. Osteoarthritis: 100mg once daily. Rheumatoid arthritis: 100mg once daily; rarely 100mg twice daily may be used.
Diclofenac Sodium Extended-release Contraindications
Aspirin allergy. Coronary artery bypass graft surgery.
Diclofenac Sodium Extended-release Boxed Warnings
Risk of serious cardiovascular and gastrointestinal events.
Diclofenac Sodium Extended-release Warnings/Precautions
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, and renal function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Elderly. Debilitated. Labor & delivery. Pregnancy (≥30 weeks gestation; avoid). Nursing mothers.
Diclofenac Sodium Extended-release Pharmacokinetics
Diclofenac Sodium Extended-release Interactions
Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors, ARBs, or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Potentiated by CYP2C9 inhibitors (eg, voriconazole) and antagonized by CYP2C9 inducers (eg, rifampin); may need dose adjustments. Caution with other hepatotoxic drugs (eg, acetaminophen, certain antibiotics, antiepileptics).
Diclofenac Sodium Extended-release Adverse Reactions
GI upset, anemia, dizziness, edema, headache, pruritus, rash (may be serious), tinnitus; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypersensitivity reactions, anemia.
Diclofenac Sodium Extended-release Clinical Trials
Diclofenac Sodium Extended-release Note
Formerly known under the brand name Voltaren-XR, Voltaren.
Diclofenac Sodium Extended-release Patient Counseling